This bill aims to prohibit the use of step therapy protocols for the treatment of neurological conditions in Minnesota. It introduces new legal language under Minnesota Statutes, chapter 62Q, specifically section 62Q.1842. The bill defines key terms such as "neurological condition," which refers to disorders causing impairment in neurological function, and "step therapy protocol," which is a method requiring patients to try less expensive treatments before more expensive ones. The legislation mandates that health plans covering neurological treatments cannot limit or exclude coverage for FDA-approved drugs included in their formulary if the drug's use aligns with FDA-approved indications and clinical practice guidelines.

The bill's provisions will take effect on January 1, 2027, and will apply to health plans that are offered, issued, or renewed on or after that date. This legislative change is intended to ensure that patients with neurological conditions have timely access to necessary medications without being subjected to potentially burdensome step therapy requirements.